ActiTarg Series · 1,700 compounds
ActiTarg-H HDAC Inhibitors
A collection of 1,700 analogs of known approved HDAC therapies across all classes, sharing fragments, scaffolds, and overall molecular similarity.
ActiTarg-H is a collection of 1,700 analogs of known approved HDAC therapies across classes, sharing fragments, scaffolds, and overall molecular similarity. Histone deacetylases (HDACs) are divided into four classes. HDACs determine the acetylation status of histones and help regulate gene expression, cell proliferation, and cell death. Inhibitors display a range of epigenetic activities studied in CNS conditions, cancers, and diabetes, among other areas.
The ActiTarg-H pool is available for cherry-picking and in custom formatting for subsets. Structural files are available for preview prior to purchase.
Molecules listed on the legacy page as partial design examples include PCI-24781, PCI-34051, erlotinib, CUDC-101, entinostat, trichostatin, LAQ824, panobinostat, belinostat, apicidin, romidepsin, vorinostat, abexinostat, valproic acid, trichostatin A, mocetinostat, givinostat, quisinostat, sulforaphane, pracinostat, hydroxamic acids, and a cyclic-peptide mimic.
Published screens
No peer-reviewed screens naming ActiTarg-H were located.
ActiTarg is one of TimTec’s targeted series. See the ActiTarg Series for the other letter collections.